Suggested remit: To appraise the clinical and cost effectiveness of mirdametinib within its marketing authorisation for for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6618
Provisional Schedule
- Expected publication:
- 03 September 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email tateam3@nice.org.uk
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- SpringWorks Therapeutics
- Others
- NHS England
- Patient carer groups
- Childhood Tumour Trust
- Nerve Tumour UK
- Professional groups
- Association of British Neurologists
- Association of Cancer Physicians
- British Paediatric Neurology Association
- Associated public health groups
- NONE
- Comparator companies
- Alexion (selumetinib) (CAU form signed, participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- NONE
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 February 2026 | Invitation to participate |
| 22 October 2025 - 19 November 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 22 October 2025 | In progress. Scoping commenced. |
| 18 August 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 28 May 2025 | Topic prioritisation |
For further information on our processes and methods, please see our CHTE processes and methods manual